Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study

NCT05427942 is registered in ClinicalTrials.gov with Celltrion HealthCare France as lead sponsor.

NCT NCT05427942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05427942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study
Lead sponsor
Celltrion HealthCare France
Phase
Observational
Overall status
Unknown status
Start date
June 3, 2022
Completion date
March 1, 2023
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylarthritis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis